PMID- 8555576
OWN - NLM
STAT- MEDLINE
DCOM- 19960226
LR  - 20190914
IS  - 1058-2916 (Print)
IS  - 1058-2916 (Linking)
VI  - 40
IP  - 3
DP  - 1994 Jul-Sep
TI  - Tumor necrosis factor monoclonal antibody prevents alterations in leukocyte 
      populations during cardiopulmonary bypass.
PG  - M554-9
AB  - Tumor necrosis factor-alpha (TNF-alpha) has been implicated as causing the 
      systemic inflammatory response to cardiopulmonary bypass (CPB) that contributes 
      to the postoperative sequelae of coagulopathy, increased capillary permeability, 
      leukocytosis, fever, and multiple organ dysfunction. To define the role of 
      TNF-alpha on leukocyte populations during CPB, pigs (n = 6) were pretreated with 
      20 mg TNF-alpha monoclonal murine antibody before normothermic CPB (2 hr) in a 
      blinded prospective randomized study with saline used as a control (n = 6). The 
      leukocyte response to CPB was measured at 10, 30, 60, and 120 min during CPB and 
      at 60 and 120 min after CPB. Repeated measures analysis of variance was performed 
      and the null hypothesis was discarded at the 5% level. The control group 
      displayed the typical leukocyte profile associated with CPB: and initial 
      leukopenia (36% reduction) followed by leukocytosis (11% increase, P = 0.0001). 
      The initial leukopenia was due to a fall in both polymorphonuclear neutrophils 
      (33% reduced, P < 0.05) and monocytes (37% reduced, P < 0.05). In the TNF-alpha 
      monoclonal murine antibody group the total leukocyte profile did not change 
      significantly from baseline, (8.7% reduction to a 16% increase, P = 0.24) nor 
      were there significant changes in populations including neutrophils and 
      lymphocytes. In the treatment group the initial reduction in monocytes was 
      prevented and total circulating monocytes increased during bypass. The 
      experimental data suggest that TNF-alpha may play an important role in the early 
      alterations in leukocyte populations associated with CPB, and TNF-alpha 
      monoclonal murine antibody pretreatment ameliorates the leukocyte response.
FAU - Vertrees, R A
AU  - Vertrees RA
AD  - Department of Surgery, University of Texas Medical Branch, Galveston 77555-0528, 
      USA.
FAU - Tao, W
AU  - Tao W
FAU - Kramer, G C
AU  - Kramer GC
FAU - Nutt, L
AU  - Nutt L
FAU - McDaniel, L B
AU  - McDaniel LB
FAU - DeVine, S D
AU  - DeVine SD
FAU - Jesmok, G
AU  - Jesmok G
FAU - Zwischenberger, J B
AU  - Zwischenberger JB
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - ASAIO J
JT  - ASAIO journal (American Society for Artificial Internal Organs : 1992)
JID - 9204109
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Tumor Necrosis Factor-alpha)
SB  - IM
MH  - Animals
MH  - Antibodies, Monoclonal/*pharmacology
MH  - Cardiopulmonary Bypass/*adverse effects
MH  - Leukocyte Count
MH  - Leukocytes/*cytology
MH  - Leukocytes, Mononuclear/cytology
MH  - Leukocytosis/etiology/prevention & control
MH  - Leukopenia/etiology/prevention & control
MH  - Neutrophils/cytology
MH  - Swine
MH  - Time Factors
MH  - Tumor Necrosis Factor-alpha/*antagonists & inhibitors/immunology/physiology
EDAT- 1994/07/01 00:00
MHDA- 1994/07/01 00:01
CRDT- 1994/07/01 00:00
PHST- 1994/07/01 00:00 [pubmed]
PHST- 1994/07/01 00:01 [medline]
PHST- 1994/07/01 00:00 [entrez]
AID - 10.1097/00002480-199407000-00060 [doi]
PST - ppublish
SO  - ASAIO J. 1994 Jul-Sep;40(3):M554-9. doi: 10.1097/00002480-199407000-00060.